Last
Update:
May 05, 2012
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
| |
|
Effects of darunavir/ritonavir-based therapy on metabolic and
anthropometric parameters in women and
men over 48 weeks.
Currier JS, Martorell C, Osiyemi O,
et al
AIDS Patient Care STDS.
2011 Jun;25(6):333-40.
Abstract
Positive Impact of HIV-1 Gag Cleavage Site Mutations on Virological
Response to Darunavir
Boosted with Ritonavir.
Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S,
t
al
Antimicrob Agents Chemother.
2011 Jan 31
Abstract
Darunavir concentrations exceed the protein-corrected
EC50 for wild-type HIV in the semen of
HIV-1-infected men.
Taylor S, Jayasuriya AN, Berry A, Gilleran G,
et al
AIDS. 2010
Aug 25
Abstract |
800 mg Darunavir tablets prepared by hot melt
extrusion.
Thommes M, Baert L, Rosier J.
Pharm Dev Technol.
2010 Aug 23.
Abstract |
Low frequency of intermittent HIV-1 semen excretion in patients treated by
darunavir/ritonavir (
600/100 mg BID) + 2 nucleoside reverse transcriptase inhibitors or monotherapy.
Lambert-Niclot S, Peytavin G, Duvivier C, et al
Antimicrob Agents Chemother.
2010 Aug 16
Abstract |
Trends in uptake of recently approved antiretrovirals within a
national healthcare system.
Belperio P, Mole L, Boothroyd D,
Backus L.
HIV Med.
2009 Oct 23.
Abstract |
Intracellular 'boosting' of darunavir using known transport
inhibitors in primary PBMC.
Kwan WS, Janneh O, Hartkoorn R, et al
Br J
Clin Pharmacol. 2009 Sep;68(3):375-80
Abstract |
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract |
Identification of new genotypic cut-off levels to predict the efficacy
of lopinavir/ritonavir and
darunavir/ritonavir in the TITAN trial.
Hill A, Marcelin AG, Calvez V.
HIV Med. 2009
Jul 6.
Abstract
|
Darunavir: A Review of its Use in the Management of HIV Infection in
Adults.
McKeage K, Perry CM, Keam SJ.
Drugs.
2009;69(4):477-503
Abstract
|
Role of tenofovir in HIV and hepatitis C virus
coinfection.
Tuma P, Vispo E, Barreiro P, Soriano V.
Enferm Infecc Microbiol Clin.
2008 Jun;26(Supl.8):31-37
Abstract
|
TMC114,
a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor
Active
against Protease Inhibitor-Resistant Viruses, Including a Broad
Range of Clinical Isolates.
De Meyer S, Azijn H, Surleraux D, et al
Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21.
Abstract
|
|
| |
FULL-TEXT ARTICLE
Pharmacokinetics and Pharmacodynamics of Darunavir and
Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender,
Race, and Clinical Experience (GRACE) Trial.
Kakuda T, Sekar V, Vis P, et al
AIDS Res Treat.
2012;2012:186987
Abstract
A WEEK-IN-REVIEW FEATURED ARTICLE
FULL-TEXT ARTICLE
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in
HIV-1Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical
Experience (GRACE) Trial
Kakuda T, Sekar V,
Vis P, et al
AIDS Research and Treatment Vol 2012 Art ID
186987
Paper
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and
raltegravir once and twice daily in HIV-infected individuals.
Jackson A, Watson V, Back D,
et
al
J Acquir Immune Defic Syndr.
2011 Sep 15.
Abstract
|
Pharmacokinetics of darunavir/ritonavir and atazanavir/ritonavir once daily over
72 hours following drug cessation.
Boffito M, Jackson A, Amara A,
et al
Antimicrob Agents Chemother.
2011 Jun 27
Abstract
Darunavir, Ritonavir and Etravirine Pharmacokinetics in the
Cervicovaginal Fluid and Blood
Plasma of HIV-Infected Women
Patterson K, Jennings S, Falcon R, et al
Antimicrob Agents Chemother.
2010 Dec 20
Abstract
|
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in
treatment experienced
patients.
Barrail-Tran A, Yazdanpanah Y, Goldwirt L, et al
AIDS.
2010 Oct 23;24(16):2581-3.
Abstract
|
Pharmacokinetics of Darunavir/r and Rifabutin Co-administered in
HIV-Negative
Healthy Volunteers.
Sekar V, Lavreys L, Van de Casteele T, et al
Antimicrob Agents Chemother.
2010 Jul 26
Abstract
|
Pharmacokinetics of darunavir at 900 milligrams and
ritonavir at 100 milligrams once daily
when coadministered with efavirenz at 600 milligrams once
daily in healthy volunteers.
Soon GH, Shen P, Yong EL,et al.
Antimicrob Agents Chemother. 2010
Jul;54(7):2775-80.
Abstract
|
Pharmacokinetics of multiple-dose darunavir in combination
with low-dose ritonavir in
individuals with mild-to-moderate hepatic impairment.
Sekar V, Spinosa-Guzman S, De Paepe E, et sl
Clin Pharmacokinet.
2010 May 1;49(5):343-50.
Abstract
|
A WEEK-IN-REVIEW FEATURED
REPORT
Pharmacokinetics of Darunavir 900mg and Ritonavir 100mg Once Daily when
Co-administered with Efavirenz 600mg Once Daily in Healthy Volunteers.
Soon GH, Shen P, Yong EL,et
al
Antimicrob Agents Chemother
2010 Apr 12
Abstract
|
Influence of darunavir coadministration on nevirapine pharmacokinetics in
HIV-infected patients:
a population approach.
Dailly E, Raffi F, Perré P, Martin J, et al
HIV Med. 2009 May 21
Abstract
|
Darunavir: pharmacokinetics and drug interactions.
Back D, Sekar V, Hoetelmans RM.
Antivir Ther. 2008;13(1):1-13.
Abstract
|
FULL-TEXT ARTICLE
Structural and thermodynamic basis for the binding of
TMC114, a next-generation human
immunodeficiency virus type 1 protease inhibitor.
King NM, Prabu-Jeyabalan M, Nalivaika EA, et al
J Virol. 2004 Nov;78(21):12012-21.
Paper |
|
| |
Factors Associated With Virological Failure in HIV-1-Infected
Patients Receiving Darunavir/Ritonavir Monotherapy.
Lambert-Niclot S, Flandre P,
Valantin MA,
et
al
J Infect Dis.
2011 Oct;204(8):1211-6
Abstract
Virological response to darunavir in patients infected with HIV
is linked to darunavi
resistance-associated mutations corrected by the count of
mutations with positive
impact and is not associated with pharmacological and combined
virological/
pharmacological parameters.
Dailly E, Rodallec A, Allavena C, Deslandes G, et al
Fundam Clin Pharmacol.
2011 May 5.
Abstract
A
WEEK-IN-REVIEW-FEATURED REPORT
Virological characterization of patients failing darunavir/ritonavir or
lopinavir/ritonavir treatment in
the ARTEMIS study:96-week analysis.
Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T,
et a|
Antivir Ther.
2011;16(1):99-108
Abstract
A WEEK IN REVIEW FEATURED
REPORT
Effect of Baseline Viral Susceptibility on Response to
Darunavir/Ritonavir versus Control Protease Inhibitors
in Treatment-Experienced HIV Type 1-Infected Patients: POWER 1 and 2.
Pozniak A, Opravil M, Beatty G, et al
AIDS Res Hum Retroviruses. 2008 Oct 9.
Abstract
|
Darunavir Inhibitory Quotient Predicts the 48-Week Virological
Response to Darunavir -Based
Salvage Therapy in HIV-infected Protease Inhibitor- Experienced Adults
Moltó J, Santos JR, Pérez-Álvarez N, Cedeńo S, et al
Antimicrob Agents Chemother. 2008 Aug 25
Abstract
|
| |
|
Selection of an M184V mutation in the cerebrospinal fluid of
a treatment-naive HIV-infected individual
starting darunavir-based therapy.
Cornelissen M, Back NK, Burger DM,
et al
Antivir Ther.
2011;16(6):931-5.
Abstract
The higher barrier of darunavir and tipranavir resistance
for HIV-1 protease.
Wang Y, Liu Z, Brunzelle JS,
et
aL
Biochem Biophys Res Commun.
2011 Sep 9;412(4):737-42
Abstract
Loss of Darunavir' s Protease Dimerization Inhibition
Activity is Associated with HIV-1 Acquisition
of Resistance to Darunavir
Koh Y, Aoki M, Danish ML, Aoki-Ogata H,
et al
J Virol. 2011
Aug 3
Abstract
FULL-TEXT ARTICLE
Prevalence and factors associated with darunavir resistance
mutations in multi-experienced HIV-1-infected patients
failing other protease inhibitors in a referral teaching
center in Brazil.
Vidal JE, Freitas AC, Song AT,
et al
Braz J Infect Dis.
2011 Jun;15(3):245-8
Paper
A WEEK-IN-REVIEW FEATURED REPORT
Virological response to darunavir in patients infected with
HIV is linked to darunavi
resistance-associated mutations corrected by the count of
mutations with positive
impact and is not associated with pharmacological and
combined virological/
pharmacological parameters.
Dailly E,
Rodallec A, Allavena C, Deslandes G, et al
Fundam Clin Pharmacol.
2011 May 5.
Abstract
Analysis of drug resistance during HIV RNA viraemia in the
MONET trial of darunavir/ritonavir
monotherapy.
Pulido F, Arribas JR, Hill A, et a
Antivir Ther.
2011;16(1):59-65.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Comparative evaluation of seven resistance interpretation algorithms
and their derived
genotypic inhibitory quotients for the prediction of 48 week
virological response to
darunavir-based salvage regimens.
Gonzalez de Requena D, Bonora S, et al
J Antimicrob Chemother.
2010 Oct 29.
Abstract |
Impact of drug transporters on cellular resistance
towards saquinavir and darunavir.
König SK, Herzog M, Theile D, et al
J Antimicrob Chemother.
2010 Sep 3
Abstract |
In Vitro Selection of Highly Darunavir-Resistant and Replication
-Competent HIV-1
Variants Using a Mixture of Clinical HIV-1 Isolates Resistant To
Multiple Conventional
Protease Inhibitors.
Koh Y, Amano M, Towata T, et al
J Virol.
2010 Sep 1.
Abstract |
A WEEK-IN-REVIEW
FEATURED REPORT
Resistance analyses in highly experienced patients failing
raltegravir, etravirine
and darunavir/ritonavir regimen.
Charpentier C, Roquebert B, Colin C, et al
AIDS. 2010 Aug 26
Abstract |
Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and
virtual phenotypic resistance patterns: an independent cohort analysis of
clinical
isolates highly resistant to all other protease inhibitors.
Talbot A, Grant P, Taylor J,
et al
Antimicrob Agents Chemother. 2010
Jun;54(6):2473-9
Abstract |
Drug Resistance Mutations in HIV-Infected Patients Failing Tipranavir
and
Darunavir in the Spanish Drug Resistance Database.
Poveda E, Anta L, Blanco JL, et al
Antimicrob Agents Chemother.
2010 May 17.
Abstract |
Predicting Tipranavir and Darunavir Resistance using Genotypic, Phenotypic
and Virtual Phenotypic Resistance Patterns: An Independent Cohort Analysis
of Clinical Isolates Highly Resistant to All Other Protease Inhibitors.
Talbot A, Grant P, Taylor J,
et al
Antimicrob Agents Chemother.
2010 Apr 5
Abstract |
A WEEK-IN-REVIEW
FEATURED REPORT
Etravirine limits the emergence of darunavir and other protease
inhibitor resistance-associated
mutations in the DUET trials.
Peeters M, Vingerhoets J, Tambuyzer
L, et al
AIDS.
2010 Feb 12.
Abstract |
Insights into drug resistance of mutations D30N and I50V to HIV-1
protease inhibitor TMC-114:
Free energy calculation and molecular dynamic simulation.
Chen J, Zhang S, Liu X, Zhang Q.
J Mol Model.
2009 Jul 24.
Abstract |
Mutations associated with virological response to darunavir/ritonavir
in HIV-1-infected
protease inhibitor-experienced patients.
Descamps D, Lambert-Niclot S, Marcelin AG, et al
J Antimicrob Chemother.
2009 Jan 15.
Abstract
|
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1
protease with highly drug
resistant mutations D30N, I50V, and L90M.
Kovalevsky AY, Tie Y, Liu F, et al
J Med Chem. 2006 Feb
23;49(4):1379-87.
Abstract |
| |
|
A WEEK-IN-REVIEW FEATURED
REPORT
Effect of Baseline Characteristics on the Efficacy and
Safety of Once-Daily Darunavir/ Ritonavir in HIV-1-Infected,
Treatment-Naďve ARTEMIS Patients at Week 96.
Fourie J, Flamm J, Rodriguez-French A,
HIV Clin Trials. 2011 Nov-Dec;12(6):313-22.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Long-term efficacy of darunavir/ritonavir monotherapy in patients with
HIV-1 viral suppression: week 96
results from the MONOI ANRS 136 study.
Valantin MA, Lambert-Niclot S, Flandre P
et al
J Antimicrob Chemother.
2011 Dec 7
Abstract
Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients:
Observational Data
from the Randomized POTENT Trial.
Elgadi MM, Piliero PJ.
Drugs R D. 2011
Oct 18.
Abstract
Factors Associated With Virological Failure in
HIV-1-Infected Patients Receiving Darunavir/Ritonavir Monotherapy.
Lambert-Niclot S, Flandre P, Valantin MA,
et
al
J Infect Dis.
2011 Oct;204(8):1211-6.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus
Raltegravir in
Treatment-Naďve HIV-1-infected Patients (ACTG A5262).
Taiwo B, Zheng L, Gallien S, et al
AIDS. 2011 Aug 19.
Abstract
Darunavir: an effective protease inhibitor for
HIV-infected patients.
Phung BC, Yeni P.
Expert Rev Anti Infect Ther.
2011 Jun;9(6):631-43
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
96 week results from the MONET trial: a randomized comparison of
darunavir/ritonavir with
versus without nucleoside analogues, for patients with HIV RNA <50
copies/mL at baseline.
Clumeck N, Rieger A, Banhegyi D,
et al
J Antimicrob Chemother. 2011
Jun 7.
Abstract
ODIN: 48-week analysis of once- versus twice-daily
darunavir/ritonavir in treatment-experienced
HIV-1-infected patients.
Cahn P, Fourie J, Grinsztejn B, Hodder S, et al
AIDS. 2011 Feb 22
Abstract
Darunavir Outcomes Study: Comparative Effectiveness of Virologic
Suppression,
Regimen Durability, and Discontinuation Reasons for Three-Class
Experienced
Patients at 48 Weeks.
Willig JH, Aban I, Nevin CR, et al
AIDS Res Hum Retroviruses.
2010 Oct 21.
Abstract |
Efficacy, tolerability and risk factors for virological failure of
darunavir-based therapy for
treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.
Young J, Scherrer A, Günthard H, et al
HIV Med. 2010 Oct 18. doi: 10.111
Abstract |
A WEEK-IN-REVIEW
FEATURED REPORT
Sex-Based Outcomes of Darunavir-Ritonavir Therapy: A Single-Group Trial.
Currier J, Averitt Bridge D, Hagins D, et al
Ann Intern Med. 2010 Sep
21;153(6):349-357
Abstract |
A WEEK-IN-REVIEW
FEATURED REPORT
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1
viral
suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
Katlama C, Valantin MA, Algarte-Genin M, et al
AIDS. 2010 Sep
24;24(15):2365-2374
Abstract |
A WEEK-IN-REVIEW
FEATURED REPORT
Efficacy of darunavir/ritonavir maintenance monotherapy in patients
with HIV-1 viral
suppression: a randomized open-label, noninferiority trial, MONOI-ANRS
136.
Katlama C, Valantin MA, Algarte-Genin M, et al
AIDS. 2010 Aug 26
Abstract |
A WEEK-IN-REVIEW
FEATURED REPORT
Efficacy, safety and pharmacokinetics of 900/100 mg of
darunavir/ritonavir once daily in
treatment-experienced patients.
Curran A, Gutirerrez M, Deig E,
et al
J Antimicrob Chemother. 2010 Aug 16
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Suboptimal adherence to darunavir/ritonavir has minimal effect on
efficacy
compared with lopinavir/ritonavir in treatment-naive, HIV-infected
patients:
96 week ARTEMIS data.
Nelson M, Girard PM, Demasi R,
et al,
J
Antimicrob Chemother.
2010 May 24.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Factors predictive of successful darunavir/ritonavir-based therapy in highly
antiretroviral-
experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C, Buyck JF, Peytavin G, et al
J
Clin Virol. 2010 Mar;47(3):248-52.
Abstract |
Factors predictive of successful darunavir/ritonavir-based therapy in highly
antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C, Buyck JF, Peytavin G, et al
J Clin Virol. 2010 Jan 21
Abstract |
The MONET trial: darunavir/ritonavir with or without nucleoside
analogues, for patients
with HIV RNA below 50 copies/ml.
Arribas JR, Horban A, Gerstoft J, et al
AIDS.
AIDS. 2010 Jan 16;24(2):223-30.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV
type-1 patients in the
POWER 1, 2 and 3 trials at week 96.
Arastéh K, Yeni P, Pozniak A, et al
Antivir Ther. 2009;14(6):859-64
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in
treatment-experienced
children and adolescents
Blanche S, Bologna R, Cahn P, et al
AIDS. 2009 Aug 30
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive,
HIV-1-infected patients:
96-week analysis.
Mills AM, Nelson M, Jayaweera D, et al
AIDS. 2009 May 29.
Abstract
|
Early virologic suppression with three-class experienced patients: 24-week
effectiveness in the
darunavir outcomes study.
McKinnell JA, Lin HY, Nevin CN, et al
AIDS. 2009 May 29
Abstract |
Characterization of virologic failure patients on darunavir/ritonavir in
treatment-experienced patients.
De Meyer S, Lathouwers E, Dierynck I,
et al
AIDS. 2009 May 25.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and Safety of Darunavir and Etravirine in an Antiretroviral
Multi-experienced Youth with
Vertically HIV-1 Infection.
Rosso R, Bernardini C, Bruzzone B,
et al
Eur J Med Res. 2009 Mar 17;14(3):136-8.
Abstract |
Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg
Once-Daily in
Treatment-Naďveand -Experienced Patients.
Boffito M, Miralles D, Hill A.
HIV Clin Trials.
2008 Jan 1;9(6):418-427
Abstract
|
Safety, Tolerability, and Efficacy of Darunavir (TMC114) with
Low-Dose Ritonavir in
Treatment-Experienced, Hepatitis B or C Co-infected Patients in
POWER 1 and 3.
Rachlis A, Clotet B, Baxter J, et al
HIV Clin Trials. 2007
Jul-Aug;8(4):213-20.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in
Treatment-Experienced
Patients: 24-Week Results of POWER 3.
Molina JM, Cohen C, Katlama C, et al
J Acquir Immune Defic Syndr. 2007 Jul 5;
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of darunavir-ritonavir compared with that of
lopinavir-ritonavir at 48 weeks
in treatment-experienced, HIV-infected patients in TITAN: a randomised
controlled phase III trial.
Madruga JV, Berger D, McMurchie M, et al
Lancet. 2007 Jul 7;370(9581):49-58.
|
A WEEK-IN-REVIEW FEATURED REPORT | | | |
General
Reports
Darunavir Main Page
Main
New/Newsworthy